The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itThe outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…
Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the…

